Study guide

3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound)

NCC Inpatient Obstetric Nursing RNC-OB

Track your progress as you read

Finished sections get a check mark.

1 Chapter 0: Introduction & How to Use This Guide

0.1 About the RNC-OB Credential & Exam Blueprint 0.2 How to Use This Study Guide & Clinical Learning Methodology

2 Chapter 1: Pregnancy Complications — Maternal Medical Conditions

1.1 Hypertensive Disorders of Pregnancy 1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy 1.3 Diabetes Mellitus in Pregnancy 1.4 Maternal Cardiac and Respiratory Disorders 1.5 Infectious Diseases in Inpatient Obstetrics 1.6 Hematologic, Endocrine, Connective Tissue & Other Systemic Disorders

3 Chapter 2: Pregnancy Complications — Preterm Labor, Multiple Gestation, Placental & Fetal Disorders

2.1 Psychosocial Disorders, Substance Use & Environmental Exposures 2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection 2.3 Multiple Gestation: Placentation, Chorionicity & Complications 2.4 Placental Disorders: Previa, Abruption, Vasa Previa & PAS 2.5 Fetal Growth Disorders & Amniotic Fluid Complications

4 Chapter 3: Antenatal Fetal Assessment & Surveillance

3.1 Antenatal Testing Methods & Indications for Fetal Surveillance 3.2 Nonstress Test (NST), Contraction Stress Test (CST) & Biophysical Profile (BPP) 3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound) 3.4 Fetal Oxygenation Physiology & Acid-Base Regulation 3.5 Umbilical Cord Blood Gas Collection & Clinical Interpretation

5 Chapter 4: Fetal Assessment & Electronic Fetal Monitoring (EFM)

4.1 NICHD Electronic Fetal Monitoring Terminology & Baseline Features 4.2 FHR Decelerations, Acceleration Patterns & Uterine Activity 4.3 The NICHD Three-Tier Fetal Heart Rate Classification System 4.4 Intrauterine Resuscitation & Clinical Action Protocols 4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation

6 Chapter 5: Labor & Birth Physiology — Mechanics, Cardinal Movements, Stages & Support

5.1 Physiology of Labor & Uterine Mechanics 5.2 Pelvic Anatomy, Fetal Lie, Presentation & Cardinal Movements of Labor 5.3 Stages of Labor, Cervical Dilatation Dynamics & Progression Guidelines 5.4 Intrapartum Admission Assessment, Obstetric Triage & Membrane Rupture Evaluation 5.5 Labor Support, Non-Pharmacologic Pain Management & Physiologic Birth Practices

7 Chapter 6: Labor & Birth Interventions — Cervical Ripening, Induction, Pain Management & Anesthesia

6.1 Bishop Scoring, Pre-Induction Cervical Ripening & Mechanical Methods 6.2 Oxytocin Administration, Titration Protocols & Uterine Tachysystole Management 6.3 Nonpharmacologic Comfort & Labor Pain Management Strategies 6.4 Systemic Opioid Analgesia & Inhaled Nitrous Oxide 6.5 Neuraxial Analgesia, Spinal/Epidural Complications & General Anesthesia

8 Chapter 7: Labor & Birth — Operative Deliveries, TOLAC/VBAC & Special Intrapartum Procedures

7.1 External Cephalic Version (ECV) & Malpresentation Management 7.2 Operative Vaginal Delivery: Vacuum Extraction & Forceps-Assisted Birth 7.3 Cesarean Delivery: Surgical Indications, Intraoperative Management & PACU Recovery 7.4 Trial of Labor After Cesarean (TOLAC) & Vaginal Birth After Cesarean (VBAC) 7.5 Special Intrapartum Procedures: Amniotomy, Amnioinfusion, Cervical Ripening & Labor Augmentation

9 Chapter 8: Obstetric Emergencies & Critical Care

8.1 Shoulder Dystocia Management & HELPERR Protocol 8.2 Umbilical Cord Prolapse & Feto-Vascular Emergencies 8.3 Uterine Rupture & Acute Uterine Inversion 8.4 Amniotic Fluid Embolism (Anaphylactoid Syndrome of Pregnancy) 8.5 Intraamniotic Infection (Chorioamnionitis) & Maternal Sepsis

10 Chapter 9: Postpartum Physiology & Immediate Recovery Care

9.1 Postpartum Physiologic Changes & Maternal Systemic Adaptations 9.2 Fourth Stage of Labor & Immediate Recovery Care 9.3 Routine Postpartum Nursing Assessment & Clinical Care (BUBBLE-HE) 9.4 Rh Isoimmunization, Alloimmunization & Postpartum Immunizations 9.5 Postpartum Discharge Teaching, Warning Signs & Maternal Safety

11 Chapter 10: Postpartum Adaptation, Hemorrhage & Clinical Complications

10.1 Postpartum Hemorrhage: Definition, Risk Stratification, 4 Ts, QBL & Pharmacotherapy 10.2 Postpartum Infections: Endometritis, Wound Infections, Sepsis & Postpartum Pyrexia 10.3 Thromboembolic Disorders: DVT, Pulmonary Embolism & Septic Pelvic Thrombophlebitis 10.4 Perinatal Mood & Anxiety Disorders: Postpartum Blues, PPD, Anxiety & Postpartum Psychosis 10.5 Lactation Physiology, Breastfeeding Complications, Engorgement & Medication Safety

12 Chapter 11: Newborn Care, Transition & Clinical Assessment

11.1 Neonatal Physiologic Transition & Cardiorespiratory Adaptation 11.2 Immediate Newborn Care, Apgar Scoring & Delivery Room Stabilization 11.3 Newborn Thermoregulation & Pathophysiology of Cold Stress 11.4 Gestational Age & Neonatal Growth Assessment 11.5 Comprehensive Newborn Head-to-Toe Examination & Normal Variants

13 Chapter 12: Newborn Complications, Resuscitation & High-Acuity Management

12.1 Neonatal Resuscitation Program (NRP 8th Edition) & Delivery Room Resuscitation 12.2 Neonatal Glucose Homeostasis, Hypoglycemia Screening & Clinical Management 12.3 Neonatal Hyperbilirubinemia, Bilirubin Metabolism & Phototherapy Protocols 12.4 Neonatal Respiratory Distress: TTN, RDS, Meconium Aspiration & Persistent Pulmonary Hypertension (PPHN) 12.5 Neonatal Sepsis, Congenital Infections & Neonatal Abstinence Syndrome (NAS/NOWS)

14 Chapter 13: Professional Practice, Legal-Ethical Frameworks, Patient Safety & Quality Improvement

13.1 Legal Aspects of Perinatal Nursing & High-Risk Documentation Standards 13.2 Ethical Principles in Perinatal Care & Maternal-Fetal Conflicts 13.3 Quality Improvement, Perinatal Safety Initiatives & AIM Bundles 13.4 Patient Safety Culture, Team Communication & Clinical Escalation 13.5 Evidence-Based Practice, Research Utilization & Perinatal Guidelines

3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound)

Key Takeaways Explain This Topic AI

Prenatal screening tests (cfDNA, serum analytes) assess statistical probability of aneuploidy (cfDNA >99% sensitive for T21 after 10 0/7 weeks), but positive screens always require diagnostic confirmation (CVS or amniocentesis) before irreversible decisions.

Chorionic Villus Sampling (CVS, 10 0/7–13 6/7 weeks) enables first-trimester genetic diagnosis via trophoblast biopsy but cannot evaluate neural tube defects (no AFP) and carries a 1–2% risk of confined placental mosaicism.

Genetic amniocentesis (performed ≥15 0/7 weeks under continuous ultrasound guidance) provides definitive karyotype and microarray analysis, measures amniotic fluid AFP and acetylcholinesterase for open neural tube defects, and evaluates intra-amniotic infection.

Percutaneous Umbilical Blood Sampling (PUBS / cordocentesis) directly accesses umbilical vein blood for definitive fetal hematocrit testing and therapeutic intrauterine transfusions, carrying a 1–2% procedure-related loss risk.

Administration of 300 mcg Rho(D) Immune Globulin (RhoGAM) intramuscularly within 72 hours is mandatory following any invasive intrauterine procedure (CVS, amniocentesis, PUBS) in unsensitized Rh-negative individuals.

Last updated: August 2026

Screening vs. Diagnostic Modalities in Prenatal Genetics

Perinatal nursing demands a clear, precise understanding of the fundamental distinction between prenatal screening tests and invasive diagnostic procedures . All pregnant individuals must be offered both screening and diagnostic options early in pregnancy regardless of maternal age or baseline risk status, supported by pre-test and post-test genetic counseling and shared decision-making. +-------------------------------------------------------------------------------------------------------------------+

| PRENATAL SCREENING VS. DIAGNOSTIC TESTING MATRIX |

+-------------------------------------------------------------------------------------------------------------------+

  • Feature Prenatal Screening Modalities Invasive Diagnostic Procedures
  • ------ ----------------------------- ------------------------------
  • Primary Modalities Cell-free DNA (cfDNA/NIPT), Quad Screen, Chorionic Villus Sampling (CVS),
  • First-Trimester Combined Screen, Ultrasound Amniocentesis, PUBS (Cordocentesis)

-------------------------------------------------------------------------------------------------------------------

  • Biological Sample Maternal peripheral venous blood; Ultrasound Placental trophoblast villi, amniocytes
  • nuchal translucency measurement in amniotic fluid, fetal umbilical blood

-------------------------------------------------------------------------------------------------------------------

  • Clinical Objective Calculates statistical probability / risk ratio Provides definitive cytogenetic,
  • of a fetal aneuploidy or structural defect chromosomal microarray, or genomic diagnosis

-------------------------------------------------------------------------------------------------------------------

Procedure Loss Risk Zero procedural risk (non-invasive blood draw) Low procedural risk (0.1% to 2.0%)

-------------------------------------------------------------------------------------------------------------------

  • Diagnostic Authority NEVER diagnostic; requires confirmatory testing Definitive (Gold Standard); guides
  • before irreversible clinical decisions management, delivery planning, or termination

+-------------------------------------------------------------------------------------------------------------------+

Non-Invasive Prenatal Screening: Cell-Free DNA (cfDNA / NIPT)

Cell-Free DNA (cfDNA) screening analyzes small fragments of cell-free extracellular DNA circulating in maternal blood. Approximately 4% to 15% of circulating cell-free DNA in maternal plasma originates from apoptotic placental syncytiotrophoblasts (termed the fetal fraction ).

Clinical Specifications

Timing: Can be drawn at any time starting from 10 0/7 weeks of gestation until term.

Scope of Screening: Highly sensitive screening for common autosomal trisomies: Trisomy 21 (Down syndrome, >99% detection rate) , Trisomy 18 (Edwards syndrome, ~98% detection) , and Trisomy 13 (Patau syndrome, ~99% detection) , as well as fetal sex and sex chromosome aneuploidies (45,X Turner syndrome; 47,XXY Klinefelter syndrome; 47,XXX; 47,XYY).

Fetal Fraction Requirement: A minimum fetal fraction of ≥4% is generally required for a valid result. Causes of low fetal fraction (resulting in a 'no-call' or inconclusive test) include early gestational age (<10 weeks), high maternal body mass index (BMI >30–35 kg/m² due to increased maternal plasma volume and adipocyte turnover), maternal use of low-molecular-weight heparin, or underlying fetal aneuploidy (notably Trisomy 13 and Triploidy).

Mechanisms of Discordant Results (False Positives / False Negatives):

Confined Placental Mosaicism (CPM): The genetic mutation exists in placental trophoblasts but not in the fetus proper (or vice versa).

Vanishing Twin: Residual apoptotic DNA from a demised co-twin persists in maternal circulation for weeks to months.

Maternal Malignancy or Maternal Mosaicism: Undiagnosed maternal chromosomal abnormalities or occult maternal neoplasms shedding abnormal DNA fragments.

Clinical Rule: A positive cfDNA screen must always be confirmed via amniocentesis or CVS prior to irreversible pregnancy termination or invasive interventions.

  • Invasive Diagnostic Procedures
  • 1. Chorionic Villus Sampling (CVS)

Gestational Timing: Performed between 10 0/7 and 13 6/7 weeks of gestation .

Technique: Under continuous real-time ultrasound guidance, a sterile catheter is inserted transcervically or an 18- to 20-gauge spinal needle is advanced transabdominally into the placenta ( chorion frondosum ) to aspirate placental chorionic villi.

Diagnostic Capability: Enables first-trimester karyotyping, chromosomal microarray (CMA), and targeted single-gene molecular testing. Limitation: CVS cannot evaluate for Open Neural Tube Defects (ONTD) because amniotic fluid alpha-fetoprotein cannot be measured; maternal serum alpha-fetoprotein (MSAFP) screening must still be performed at 15–20 weeks.

Procedure-Related Risks: Pregnancy loss rate of approximately 0.2% to 0.5% (1 in 200 to 1 in 500). If performed prior to 10 0/7 weeks, CVS is associated with severe limb reduction defects (transverse limb deficiency) and micrognathia.

2. Amniocentesis

Gestational Timing: Performed from 15 0/7 weeks of gestation onward (typically 15 to 20 weeks for genetic evaluation; third trimester for infectious or lung maturity assessment).

Technique: Under continuous ultrasound visualization, a 20- to 22-gauge spinal needle is advanced transabdominally through the maternal abdominal wall and myometrium into a clear pocket of amniotic fluid, avoiding the fetus and placenta. The initial 1 to 2 mL of fluid is discarded to prevent maternal cell contamination; 15 to 30 mL of clear amniotic fluid is aspirated into sterile, light-shielded syringes.

Diagnostic Indications and Analysis:

Cytogenetics & Genomics: Karyotyping (detects aneuploidies and large translocations; takes 7–14 days) and Chromosomal Microarray (CMA, detects microdeletions and microduplications <5–10 Mb; takes 5–7 days).

Open Neural Tube Defects (ONTD): Elevated Amniotic Fluid Alpha-Fetoprotein (AFAFP) confirmed by the presence of Acetylcholinesterase (AChE) is diagnostic for open neural tube defects (anencephaly, myelomeningocele) and ventral wall defects (gastroschisis, omphalocele).

Intra-Amniotic Infection (Chorioamnionitis): Fluid analysis showing low glucose (<14 mg/dL), elevated lactate dehydrogenase (LDH), elevated leukocyte count, positive Gram stain, or positive microbial PCR/culture.

Fetal Lung Maturity (Historical / Specific Refractory Cases): Lecithin-to-Sphingomyelin (L/S) ratio ≥2.0 and presence of Phosphatidylglycerol (PG) indicates mature fetal surfactant (L/S ≥3.0 in maternal diabetes).

Procedure-Related Risks: Loss rate is approximately 0.1% to 0.3% (1 in 300 to 1 in 1,000 in modern experienced centers). Complications include transient uterine cramping (1–2%), transient amniotic fluid leakage (1%), intra-amniotic infection (<0.1%), and fetomaternal hemorrhage.

3. Percutaneous Umbilical Blood Sampling (PUBS / Cordocentesis)

Gestational Timing: Performed after 18 0/7 weeks of gestation .

Technique: Under direct ultrasound guidance, a 20- to 22-gauge needle is inserted into the umbilical vein at its insertion site into the placenta (where the cord is anchored and immobile).

Indications: Direct assessment of fetal hematocrit/hemoglobin in severe fetal anemia (due to Rh isoimmunization or parvovirus), emergency fetal platelet transfusion for alloimmune thrombocytopenia, and delivery of Intrauterine Blood Transfusion (IUT) using cross-matched, irradiated, CMV-negative, O-negative packed red blood cells.

Risks: Highest complication rate among invasive procedures: 1.0% to 2.0% procedure-related loss , cord vessel laceration, cord hematoma, severe refractory fetal bradycardia (often requiring emergency cesarean delivery), and massive fetomaternal hemorrhage. +-------------------------------------------------------------------------------------------------------------------+

| COMPARISON OF INVASIVE PRENATAL PROCEDURES |

+-------------------------------------------------------------------------------------------------------------------+

  • Procedure Gestational Window Tissue Sampled Primary Advantages Key Limitations
  • -------- ------------------ -------------- ------------------ ---------------
  • Chorionic Villus 10 0/7 to 13 6/7 wks Chorionic Villi First-trimester diagnosis; Cannot test for ONTD;
  • Sampling (CVS) (Placental tissue) Rapid preliminary FISH 1-2% placental mosaicism

-------------------------------------------------------------------------------------------------------------------

  • Amniocentesis ≥ 15 0/7 weeks Amniocytes in Definitive genetic analysis; Second trimester timing;
  • (typically 15-20 wks) Amniotic Fluid AFAFP & AChE for ONTD; Loss rate 0.1-0.3%
  • Infection & maturity markers

-------------------------------------------------------------------------------------------------------------------

  • PUBS / ≥ 18 0/7 weeks Fetal Umbilical Direct fetal hematocrit; Highest loss risk (1-2%);
  • Cordocentesis Venous Blood Allows direct intrauterine Cord hematoma / bradycardia
  • blood transfusion

+-------------------------------------------------------------------------------------------------------------------+

  • Inpatient Obstetric Nursing Care & Safety Protocols
  • Pre-Procedure Nursing Care

Informed Consent & Patient Education: Verify signed informed consent; ensure the patient understands procedural risks, benefits, and diagnostic limitations.

Baseline Maternal-Fetal Assessment: Record maternal baseline vital signs. Perform a baseline electronic fetal monitoring (EFM) strip or document fetal heart rate viability via Doppler/ultrasound prior to prep.

Bladder Protocol:

For early CVS (<12 weeks) or early amniocentesis , a full bladder is often requested to push the anteverted uterus upward into the abdominal field.

For second-trimester amniocentesis (≥15 weeks) , an empty bladder is mandatory to prevent accidental bladder puncture by the needle.

Intra-Procedure Nursing Responsibilities

Maintain strict aseptic technique, assist with sterile transducer draping, provide continuous emotional support, and encourage deep relaxation breathing (instructing the patient to avoid sudden body movements or deep coughing during needle insertion).

Post-Procedure Nursing Interventions & Monitoring

Post-Procedure Fetal Monitoring: Continuous external EFM (or ultrasound FHR verification) for 30 to 60 minutes post-procedure to evaluate for fetal bradycardia, prolonged decelerations, or loss of variability.

Maternal Discharge Instructions: Instruct patient to rest for 24 hours and report immediately for: fever (>100.4°F / 38.0°C), chills, severe persistent uterine cramping, leakage of fluid from the vagina, active vaginal bleeding, or decreased fetal movement.

MANDATORY Rho(D) IMMUNE GLOBULIN (RhoGAM) ADMINISTRATION:

Any unsensitized Rh-negative pregnant individual undergoing an invasive procedure (CVS, amniocentesis, PUBS, external cephalic version) is at high risk for fetomaternal hemorrhage and isoimmunization.

Standard Dosing: Administer 300 mcg (1,500 IU) Rho(D) Immune Globulin intramuscularly within 72 hours of the procedure (50 mcg dose is acceptable for first-trimester procedures before 13 0/7 weeks if 300 mcg is unavailable).

Loading diagram... Prenatal Diagnostic Decision Algorithm